129 filings
10-Q
2024 Q1
ELVN
Enliven Therapeutics Inc
Quarterly report
14 May 24
4:15pm
8-K
ELVN
Enliven Therapeutics Inc
14 May 24
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
4:10pm
EFFECT
ELVN
Enliven Therapeutics Inc
1 May 24
Notice of effectiveness
12:15am
424B3
ELVN
Enliven Therapeutics Inc
30 Apr 24
Prospectus supplement
4:16pm
ARS
2023 FY
ELVN
Enliven Therapeutics Inc
26 Apr 24
Annual report to shareholders
4:16pm
DEFA14A
lt45ybu2pie8ks5
26 Apr 24
Additional proxy soliciting materials
4:11pm
PRE 14A
cu0d dbf46ia6a47s
15 Apr 24
Preliminary proxy
4:05pm
8-K
s1lmiyo
11 Apr 24
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
8:02am
8-K
ula3jud221ndm4yrpz
9 Apr 24
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
4:14pm
D
ab7om
3 Apr 24
$90.00 mm in equity / options / securities to be acquired, sold $90.00 mm, 20 investors
5:07pm
8-K
vpvhxad 7lts4swe3
19 Mar 24
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
8:46am
S-8
6xc53nmkk88ytwqca4wo
14 Mar 24
Registration of securities for employees
5:15pm
8-K
8p7cska698i2z8
14 Mar 24
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
4:10pm
8-K
7zrbocbl1ok9hl0z u1
9 Nov 23
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:10pm
8-K
0fzzr8jlad hbx1m2nv6
10 Aug 23
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:10pm